Biofarm (BSE:BIO) Margin of Safety % (DCF Earnings Based): 31.59% (As of Jun. 30, 2026)


BSE:BIO Biofarm SA BSE:BIO
70 GF Score
Price lei1.38
GF Value lei0.86
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm Margin of Safety % (DCF Earnings Based)?

Biofarm BSE:BIO -8.03% 70 Margin of Safety % (DCF Earnings Based) is 31.59% as of Jun. 30, 2026. GuruFocus rates BSE:BIO with a GF Score™ of 70/100 and a GF Value™ of lei0.86 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-30), Biofarm's Predictability Rank is 4.5-Stars. Biofarm's intrinsic value calculated from the Discounted Earnings model is lei2.01 and current share price is lei1.375. Consequently,

Biofarm's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 31.59%.

BSE:BIO vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofarm Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Biofarm's Margin of Safety % (DCF Earnings Based) falls into.


BSE:BIO
70GF Score
Biofarm SA BSE:BIO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Margin of Safety % (DCF Earnings Based) Calculation

Biofarm's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(2.01-1.375)/2.01
=31.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of 31.59% mean?
Biofarm (BSE:BIO) has a Margin of Safety % (DCF Earnings Based) of 31.59% as of Jun. 30, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Biofarm.
Is Biofarm's Margin of Safety % (DCF Earnings Based) too high?
Biofarm's current Margin of Safety % (DCF Earnings Based) is 31.59%. Overall, Biofarm has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Biofarm's Margin of Safety % (DCF Earnings Based) of 31.59% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Biofarm. Biofarm's current Margin of Safety % (DCF Earnings Based) is 31.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.86, compared to a current price of lei1.38 — trading 59.9% above its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is 31.59%. Biofarm's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Margin of Safety % (DCF Earnings Based) is 31.59% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.38 is trading 59.9% above its estimated GF Value™ of lei0.86. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Margin of Safety % (DCF Earnings Based): 31.59%
  • GF Value™: lei0.86 vs. price of lei1.38 (59.9% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score

Get the complete analysis for BSE:BIO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.38
Price
lei0.86
GF Value